Astrana Health (NASDAQ:ASTH – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.
Valuation & Earnings
This table compares Astrana Health and GeneDx”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Astrana Health | $3.18 billion | 0.71 | $22.49 million | $0.82 | 49.77 |
| GeneDx | $454.43 million | 5.12 | -$21.02 million | ($3.64) | -21.45 |
Risk and Volatility
Astrana Health has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.
Institutional and Insider Ownership
52.8% of Astrana Health shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 20.3% of Astrana Health shares are owned by insiders. Comparatively, 25.2% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Astrana Health and GeneDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Astrana Health | 1.05% | 10.30% | 3.67% |
| GeneDx | -23.41% | 4.12% | 2.26% |
Analyst Recommendations
This is a summary of recent recommendations for Astrana Health and GeneDx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Astrana Health | 0 | 2 | 7 | 0 | 2.78 |
| GeneDx | 1 | 1 | 7 | 0 | 2.67 |
Astrana Health currently has a consensus price target of $49.43, indicating a potential upside of 21.12%. GeneDx has a consensus price target of $89.57, indicating a potential upside of 14.72%. Given Astrana Health’s stronger consensus rating and higher possible upside, equities analysts clearly believe Astrana Health is more favorable than GeneDx.
Summary
Astrana Health beats GeneDx on 9 of the 13 factors compared between the two stocks.
About Astrana Health
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.